Jain Global’s Larimar Therapeutics LRMR Stock Holding History

Jain Global’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,729	Closed	-$36K	–	1442
2025 Q1	$36K	Sell	16,729 -15,058	-47%	-$47.6K	﹤0.01%	1024
2024 Q4	$123K	Buy	+31,787	New	+$210K	﹤0.01%	682

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jain Global's LRMR Position: Q2 2025 in Review

Jain Global sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 16,729 shares — an estimated $36K sold.

Jain Global first reported a position in LRMR in Q4 2024 and held it in 2 quarters. The position peaked at $123K in Q4 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

Jain Global reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
Jain Global sold 16,729 Larimar Therapeutics shares in Q2 2025, an estimated $36K.
Jain Global first reported a position in Larimar Therapeutics in Q4 2024 and held it in 2 quarters.
Jain Global's Larimar Therapeutics position peaked at $123K in Q4 2024.
116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Jain Global's 13F filing for Q2 2025, filed 14 Aug 2025.